Clinical Trials
55 trialsStudy of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Ruijin Hospital
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Relyage
Centre Hospitalier Universitaire, Amiens
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Reduced Chemotherapy in Low Risk DLBCL
Ruijin Hospital
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
R2DLBCL80
Guangdong Provincial People's Hospital
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
ChineseAMS
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
DR-CHOP
Ruijin Hospital
LEGEND
Royal Marsden NHS Foundation Trust
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
The First Affiliated Hospital with Nanjing Medical University
Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Chidamide Plus R-CHOP in Elderly DLBCL
Ruijin Hospital
R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL
Nanfang Hospital, Southern Medical University
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
Xinjiang Medical University
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma
Hebei Medical University Fourth Hospital
STORM
University Hospital Heidelberg
Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL
Asan Medical Center
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
Pusan National University Hospital
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
Sinocelltech Ltd.
CyBeR-Lymph
University Hospital, Caen
PTLD
Asan Medical Center
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
Sun Yat-sen University
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma
Fudan University
Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL
Fudan University
Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
Chonnam National University Hospital
DLCL04
Fondazione Italiana Linfomi - ETS